Screener
Spyre Therapeutics, Inc. SYRE Free cash flow margin
Discontinued — last reported Q4 '22
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Spyre Therapeutics, Inc.’s 10-K, filed February 27, 2025. Open the filing →
- Filed
- Feb 27, 2025
- Fiscal year
- FY2024
- Accession
- 0001636282-25-000020
FAQ
- What is Spyre Therapeutics, Inc.'s free cash flow margin?
- Spyre Therapeutics, Inc. (SYRE) reported free cash flow margin of -3,442.8% in Q4 2022.
- How has Spyre Therapeutics, Inc.'s free cash flow margin changed year-over-year?
- Spyre Therapeutics, Inc.'s free cash flow margin decreased by 1045.1% year-over-year, from -300.7% to -3,442.8%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.
Ask your AI about Spyre Therapeutics, Inc.'s free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude